The Food and Drug Administration (FDA)-approved biomarkers can be surrogate, prognostic, predictive, or pharmacodynamics [16] and some of them provided a cornerstone of modern cancer therapies, as the case of prognostic and predictive biomarkers p53 [17] and Ki-67 [18] that gained clinical utility in breast cancer too [19]. Here, MKI67 is linked to breast carcinoma.